The National Cell Repository for Alzheimer's Disease (NCRAD) plays a key role in the National Institute on Aging's (NIA) efforts to identify those at risk for Alzheimer disease (AD) and develop improved treatments to delay or prevent disease onset. NCRAD was established as a cooperative agreement with the NIA to serve as the biospecimen core for all NIA-funded dementia studies. Under the advisement of NIA and the NCRAD Executive Committee (NEC), it is the mission of NCRAD to remove critical barriers hindering research progress to understand the etiology of dementia. To achieve this goal, NCRAD has two primary functions: sample banking and sample distribution. This application is in response to a request by NIA to continue the support for NCRAD (PAR-15-316). NCRAD will work closely with other national efforts in AD research to achieve the following specific aims:
Aim 1 : To provide a state-of-the-art central biospecimen repository for all NIA-funded dementia studies.
Aim 2 : To facilitate and foster sample sharing to all qualified investigators.
This application proposes to renewal the National Cell Repository for Alzheimer Disease (NCRAD), an NIA funded repository for dementia-related studies. NCRAD will work closely with NIA, studies banking samples, as well as researchers requesting samples to ensure that the biospecimens banked at NCRAD are of the highest quality. These biospecimens will be used to perform research with the ultimate goal of developing new treatments for Alzheimer disease and other types of dementia.
|Chen, Jason A; Chen, Zhongbo; Won, Hyejung et al. (2018) Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. Mol Neurodegener 13:41|
|Raghavan, Neha S; Brickman, Adam M; Andrews, Howard et al. (2018) Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer's disease. Ann Clin Transl Neurol 5:832-842|
|Miller, Jason E; Shivakumar, Manu K; Risacher, Shannon L et al. (2018) Codon bias among synonymous rare variants is associated with Alzheimer's disease imaging biomarker. Pac Symp Biocomput 23:365-376|
|Miller, Jason E; Shivakumar, Manu K; Lee, Younghee et al. (2018) Rare variants in the splicing regulatory elements of EXOC3L4 are associated with brain glucose metabolism in Alzheimer's disease. BMC Med Genomics 11:76|
|Ikezu, Tsuneya; Chen, Cidi; DeLeo, Annina M et al. (2018) Tau Phosphorylation is Impacted by Rare AKAP9 Mutations Associated with Alzheimer Disease in African Americans. J Neuroimmune Pharmacol 13:254-264|
|Roostaei, Tina; Felsky, Daniel; Nazeri, Arash et al. (2018) Genetic influence of plasma homocysteine on Alzheimer's disease. Neurobiol Aging 62:243.e7-243.e14|
|Lobach, Iryna; Sampson, Joshua; Alekseyenko, Alexander et al. (2018) Case-control studies of gene-environment interactions. When a case might not be the case. PLoS One 13:e0201140|
|Zhou, Zilu; Wang, Weixin; Wang, Li-San et al. (2018) Integrative DNA copy number detection and genotyping from sequencing and array-based platforms. Bioinformatics 34:2349-2355|
|Ridge, Perry G; Wadsworth, Mark E; Miller, Justin B et al. (2018) Assembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping. Alzheimers Dement 14:514-519|
|Wang, Jen-Chyong; Alinaghi, Somayeh; Tafakhori, Abbas et al. (2018) Genetic screening in two Iranian families with early-onset Alzheimer's disease identified a novel PSEN1 mutation. Neurobiol Aging 62:244.e15-244.e17|
Showing the most recent 10 out of 422 publications